

# Halitosis: a new definition and classification

M. Aydin\*<sup>1</sup> and C. N. Harvey-Woodworth<sup>2</sup>

## IN BRIEF

- Suggests previous halitosis classification systems omit some aetiologies, and their diagnoses hinged on single occasion halitometric and organoleptic findings, which are unreliable.
- Proposes halitosis diagnosis should focus more on the declarations of the patient and his/her social environment.
- Suggests the new classification completely covers all possible aetiologies of halitosis.

**Background** There is no universally accepted, precise definition, nor standardisation in terminology and classification of halitosis. **Objective** To propose a new definition, free from subjective descriptions (faecal, fish odour, etc), one-time sulphide detector readings and organoleptic estimation of odour levels, and excludes temporary exogenous odours (for example, from dietary sources). Some terms previously used in the literature are revised. **Results** A new aetiologic classification is proposed, dividing pathologic halitosis into Type 1 (oral), Type 2 (airway), Type 3 (gastroesophageal), Type 4 (blood-borne) and Type 5 (subjective). In reality, any halitosis complaint is potentially the sum of these types in any combination, superimposed on the Type 0 (physiologic odour) present in health. **Conclusion** This system allows for multiple diagnoses in the same patient, reflecting the multifactorial nature of the complaint. It represents the most accurate model to understand halitosis and forms an efficient and logical basis for clinical management of the complaint.

## LITERATURE REVIEW

### Previous definitions

Halitosis is receiving increasing scientific interest, but still no accepted definition exists. In the literature, definitions include: 'the subjective perception after smelling someone's breath, if unpleasant',<sup>1</sup> 'noticeably unpleasant odours exhaled in breathing',<sup>2</sup> 'an oral health condition characterised by unpleasant odours emanating consistently from oral cavity',<sup>3</sup> 'general term to describe any disagreeable odour of breath, regardless of its origin',<sup>4</sup> and 'an unpleasant odour emanating from oral cavity'.<sup>5</sup>

Many definitions are inadequate, ignoring the potential emanation of odours via the mouth and nose from the respiratory and gastroesophageal tracts, transfer of volatiles from blood to breath during alveolar gas exchange, and also self-perception of halitosis by the patient. To varying degrees the breath always has odorant volatiles, originating orally or elsewhere. None set a clear boundary between normal, physiologic breath odour and, pathologic halitosis. Negative identification of an odour requires qualification. Who determines this? The patient, the patient's social environment,

<sup>1</sup>Private practice, Turkey; <sup>2</sup>Private practice, London  
\*Correspondence to: Dr Murat Aydin  
Email: aydinmur@gmail.com




Fig. 1 Two previous classifications. Miyazaki *et al.* 1999 is generally the most widely used, but neither is universally accepted<sup>5</sup>

or the clinician by sulphide detectors (halitometers)? Some refer to exogenous odorants (for example, garlic) as halitosis, yet this is not pathologic. To distinguish normality from disease, a more precise definition and classification is needed.

This paper reviews previous attempts at classification and definition of halitosis and forwards a new scheme. The diagnosis and treatment of halitosis according to this scheme are discussed in a separate publication.

### Previous classifications

Miyazaki *et al.*<sup>6</sup> suggest genuine halitosis, pseudo-halitosis and halitophobia (Fig. 1). Genuine halitosis is divided into physiological or pathological, then the latter is split into oral and extra-oral. This was adapted

to North American society with regards to halitophobia, and appeared in publications a decade ago.<sup>7-9</sup> This classification is inflexible since multiple diagnoses for one patient are not enabled. The broad category 'extra-oral, pathologic halitosis' does not aid referral choice or help the receiving clinician, and is also poor for researchers who need to precisely classify extra-oral halitosis according to aetiology. 'Morning breath' is not placed in the oral category, despite manifesting orally. Inappropriately, two out of three categories (pseudo-halitosis and halitophobia) have psychopathologic connotations and they are excluded from pathologic halitosis. Subjective halitosis can be caused by psychologic or neurologic factors, which are technically extra-oral processes,

yet 'extra-oral halitosis' is again excluded from pathologic halitosis. After treatment, whether for genuine halitosis or pseudo-halitosis, if the patients continue to believe they have halitosis, reclassification to halitophobia occurs. This categorises cases according to treatment outcome, as halitophobia is diagnosed following a failed treatment. This scheme claims to provide treatment needs, but how can these be determined beforehand if they depend on results of treatment? Pseudo-halitosis is misleading when considered alongside other medical terms, for example, pseudo-Cushing's syndrome, intestinal pseudo-obstruction, pseudo-lymphoma or pseudo-Kaposi's sarcoma. These exist as physical entities that masquerade as their namesake. Pseudo-halitosis implies a genuine, physical condition mistaken for non-existent halitosis. Similarly, halitophobia suggests an irrational fear, but instead refers to where the patients believe their treatment unsuccessful.

Tangerman and Winkel suggest intra- and extra-oral halitosis, the latter then divided into non-blood-borne and blood-borne.<sup>10</sup> An earlier publication divides extra-oral halitosis into blood-borne, upper respiratory tract and lower respiratory tract.<sup>11</sup> They list four aetiological mechanisms of blood-borne halitosis: systemic diseases, metabolic disorders, food and medications.<sup>10</sup> These authors use 'pseudo-halitosis/halitophobia' to describe no measurable halitosis, while retaining their own classification for measurable halitosis.<sup>12</sup> In reality, this classification focuses on oral and blood-borne halitosis, with insufficient categorisation of physiologic, sinonasal, laryngopharyngeal, gastroesophageal or psychologic causes. The significance of blood-borne halitosis relative to other extra-oral mechanisms is unclear and a broad division into blood-borne and non-blood-borne may be inappropriate. Again, this system does not allow for multiple diagnoses, making accurate categorisation of some cases difficult, and there is no distinction between pathologic and physiologic halitosis.

Motta *et al.* suggest primary halitosis ('respiration exhaled by the lungs'), and secondary halitosis ('originates in mouth or upper airways').<sup>13</sup> It is unclear if primary halitosis refers to blood-borne halitosis, odour from the lower respiratory tract itself, or both. This is seldom used, perhaps because the clinical utility is limited by not addressing subjective halitosis or gastroesophageal halitosis.

### Previous terminology

In some cases, odour is not detected organoleptically and volatile sulphur

compound (VSC) levels are normal. There is no local or systemic condition and no reliable, third party confidants confirming the complaint. This scenario is generally ascribed to psychologic factors, termed imaginary halitosis,<sup>14</sup> delusional halitosis,<sup>15</sup> pseudo-halitosis,<sup>7</sup> non-genuine halitosis,<sup>16,17</sup> chronic olfactory paranoid syndrome,<sup>18</sup> anthropophobia (taijin kyofusho),<sup>19</sup> halitophobia,<sup>20</sup> olfactory reference syndrome (ORS),<sup>21,22</sup> and social anxiety disorder.<sup>23</sup> These terms may easily cause confusion.

The term psychosomatic halitosis is incorrectly used when referring to subjective halitosis complaints. Psychosomatic disorders are disorders in which psychologic factors play a significant role and there are physical symptoms that are detectable clinically. However, the term psychosomatic halitosis is used to describe an odour that is clinically non-existent.

Terms that refer to odour character promote confusion for clinicians and patients, for example sulphurous/faecal, fruity, and ammoniacal/urine-like; respectively attributed to VSC, acetone, and ammonia with other amines.<sup>10</sup> Sweet, musty or fishy are used to describe particular halitosis types. However, fish odour is non-specific for trimethylaminuria (TMAU),<sup>24</sup> as is acetone for diabetes. All individuals have detectable breath acetone >400 ppb,<sup>25,26</sup> especially when fasting. Fish odour can be perceived as musty and acetone as sweet. The sweet, musty aroma in liver failure has been termed fetor hepaticus.<sup>27</sup> This is also described as faecal, 'the smell of dead mice' or 'the breath of the dead'.<sup>28</sup>

Other terms include 'denture odour',<sup>29</sup> 'uraemic fetor' in renal failure,<sup>30</sup> and 'rotten egg' in poor oral hygiene. All these terms are subjective and open to misinterpretation. There is no standardisation in terminology, which has led to discrepancies developing where some authors use a term with one definition and others with different meaning.

- Oral malodour, oral halitosis, tongue malodour, odontogenic halitosis, pathological halitosis, objective halitosis, genuine halitosis and intra-oral halitosis are used incorrectly as synonyms for halitosis.<sup>31</sup> For example, oral malodour includes all odours originating orally, not just the tongue; but not all pathologic/objective halitosis originates orally
- Pseudo-halitosis, psychosomatic halitosis, halitophobia, self-halitosis, imaginary halitosis non-genuine halitosis, delusional halitosis and phantom halitosis are also sometimes used interchangeably,<sup>32</sup> but they not synonymous, for example, halitophobia describes a fear; self-halitosis describes

clinically existent, self-producing odour; imaginary halitosis describes halitosis produced psychologically; and phantom halitosis is neurologic

- Morning breath is sometimes used instead of physiologic halitosis, but these are also dissimilar. Not all 'morning breath' is physiologic.

### NEW DEFINITION OF HALITOSIS

Objective halitosis has been defined as 'malodour with intensity beyond a socially acceptable level perceived'.<sup>7</sup> This is independent from halitometric readings and subjective odour descriptions. This should be a basic definition of objective halitosis, but must be qualified with several important points:

- A halitosis complaint may be objective, where there is an unpleasant odour endogenously produced anywhere in the body, emitted from the mouth and/or nose and detectable to others; or subjective, where there is no detectable odour to others but the patient complains of its presence
- Anyone who complains of halitosis, objective or subjective, should be considered a 'halitosis patient'
- Evidence of objective halitosis is a clinical picture built of (i) reliable reports from the patient's social environment for example, family members or close friends, (ii) patient's self declaration of halitosis, and to a lesser extent (iii) halitometric readings
- A lack of complaints from the patient's social environment including family members, suggests that there is no objective halitosis. Furthermore, if there are no complaints from either the patient or his/her social environment, this usually implies that there is no need to diagnose halitosis or treat, even if halitometric measurements appear to indicate the presence of elevated VSC. As a rule, halitometers measure VSC, not halitosis
- Halitosis is considered unpleasant by the patient and his/her social environment. If the odour is not perceived negatively, it is not halitosis
- Halitosis is almost always chronic in nature, although it may be intermittent
- Some diseases (tonsillitis, pharyngitis, etc) or transient oral flora or metabolic changes in the body may cause bad odour in the short term (<2 months), which disappears when the condition resolves. Such bad odours are called temporary halitosis
- Some volatile foodstuffs possess specific odours (for example, garlic, onion) and may cause short term halitosis ('dietary




Fig. 2 New etiologic classification proposed

Table 1 Outlines the differences between Type 0 and Type 1 halitosis. Physiologic halitosis should not be confused with a low level of oral (Type 1) halitosis since there are differences

	Type 0	Type 1
Duration	Always present; fluctuating	While a cause exists
Originates	Mouth + elsewhere	Mouth only
Detectable on	Mouth air + breath	Mouth air
Offensive	Possibly	Yes
Treatable	No	Yes
Preventable	No	Yes
Detectable by halitometer	Yes	Yes

odour'), as with certain medications or intoxications. All are called temporary halitosis, managed with reassurance and advice, and further diagnosis or treatment is unnecessary.

## NEW CLASSIFICATION OF HALITOSIS

Types 1-5 (Fig. 2) represent different odour mechanisms, which may be present in any combination at any time. Potentially, each type of pathologic halitosis (Type 1-5) is superimposed on physiologic odour (Type 0). At any given time, pathologic halitosis is the sum of the all these types sources, as well as their respective underlying physiologic contributions.

The relative contributions of these different physiologic and pathologic aetiologies is subject to interpersonal variation and may fluctuate even within hours in the same individual. Sometimes the level of one or more types may be so

low as to give negligible contributions to the overall complaint, or there may be multiple contributing factors in the same patient. This can be recorded as Type 1 + 3, Type 2 + 4, Type 1 + 4 + 5 halitosis, *etc.* Previous classifications oversimplify halitosis, and this new classification is the most representative model proposed.

### Type 0 halitosis: physiologic halitosis

Type 0 halitosis represents the sum of the physiologic contributions of oral, airway, gastroesophageal, blood-borne and subjective halitosis that are potentially present in every healthy person, in any combination. All healthy individuals have a certain level of bacterial activity in the mouth and on respiratory tract mucosae. In addition there is a potentially a negligible amount of gas leakage from the gastroesophageal tract, and blood gases are transferred to the exhaled breath during gas

exchange in pulmonary alveoli. Therefore, minimal amounts of Types 1-5 potentially exist in health. The total level of odour and the relative contributions of these different sources of physiologic odour is subject to both interpersonal variation, and also variation in the same individual from one occasion to the next. One or multiple types may exist in any combination at any time, varying according to many different factors, including hydration, oral hygiene, microbiota, salivary flow rate, nature of last food consumption, biochemical, hormonal, mechanic activity of the body, fasting, sleep, digestive enzyme profile in gut, momentarily amino acid and electrolyte profile in serum *etc.* It is distinguished from oral halitosis (Table 1).

### Type 1 halitosis: oral halitosis

The gases that contribute to Type 1 (oral) halitosis are (greatest to least): VSC, volatile organic compounds (VOC) and nitrogen containing gases (amines).<sup>33</sup> The main VSC involved are hydrogen sulphide ( $H_2S$ ), methyl sulphide ( $CH_3SH$ , or methyl mercaptan, MM), and dimethyl sulphide [ $(CH_3)_2S$ , DMS]. Nearly 700 different compounds have been detected orally,<sup>34</sup> including indole, skatole, acetic acid and short chain acids (for example, butyric, valeric, isovaleric, lactic, caproic, propionic and succinic acids). In halitosis patients, the 30 most abundant VOC in mouth air are alkanes or alkane derivatives, and of these the most common are methyl benzene, tetramethyl butane, and ethanol.<sup>35</sup> Alkanes are aromatic breakdown products from reactive oxygen species acting on inflamed tissues.<sup>35</sup> Others report acetone, methenamine, isoprene, phenol, and *D*-limonene are the most abundant organic compounds in mouth air in oral halitosis patients. The organoleptic level of oral halitosis correlates with VSC,<sup>34</sup> and amines (such as putrescine, cadaverine, and trimethylamine).<sup>36</sup>

The gases responsible for oral halitosis are by-products of protein and glycoprotein putrefaction by the oral microbiota. The dorso-posterior tongue is the most important halitogenic site, by virtue of having both the largest surface area and the highest bacterial load, within a densely populated biofilm.<sup>37-39</sup> About 85% of oral halitosis cases are caused by poor oral hygiene, plaque stagnation areas, gingivitis, and tongue coating.<sup>31</sup> However, a degree of oral bacterial action is continuously present in health, even with impeccable oral hygiene, and this constitutes the physiologic part of Type 1 halitosis.

Specific bacteria, especially anaerobes, are suggested to cause oral halitosis.<sup>40,41</sup> In reality, most oral bacteria are potentially

odorogenic, releasing VSC, VOC and/or amines. Depending upon the constituents of the gas produced by oral bacteria and ecologic factors in the mouth (for example, microbiota compositional fluctuations, available nutritional substrate, bacterial metabolism) momentarily determine the composition and level of odour. Therefore, the diagnostic value of the odour character at any one time is questionable. To consider some bacteria as odorogenic and others as non-odorogenic is oversimplification. In reality every bacterium is odorogenic, and there is a continuous spectrum from low to high degree of odour formation capability.<sup>33,42</sup>

Other possible origins of oral halitosis include: periodontal disease, acute necrotising ulcerative gingivitis, osteoradionecrosis, large carious cavities, blood/thrombi (for example, extraction sockets), ulceration, interdental food packing, oral prostheses (dentures, orthodontic appliances, bridges).

### Type 2 halitosis: airway halitosis

Type 2 halitosis originates from the respiratory tract itself (rhinosinusitis, tonsillitis, pharyngitis, laryngitis, bronchitis, pneumonia), anywhere from nose to alveoli. Odorous gases produced by various respiratory pathoses are held in the exhaled breath and expressed via the nose or mouth. This should be distinguished from Type 4 (blood-borne) halitosis, where volatiles from the systemic circulation are transferred during gas exchange to the breath. Some studies report the proportion of halitosis cases that are due to upper respiratory tract pathology to be between 2.9 and 10%.<sup>31,43-47</sup>

Halitosis is considered a regional symptom of chronic rhinosinusitis, and some report as many as 50-70% will complain of halitosis.<sup>48,49</sup> In paediatric patients, one of most frequent symptoms is halitosis together with cough, rhinorrhoea and sniffing,<sup>50</sup> even when nasal obstruction, post-nasal exudate, pain, sneezing and secretion are clinically absent.<sup>51</sup> Sinonasal anatomic variations (for example, agger nasi cells, pneumatization of turbinates or septum; deviated nasal septum) are very commonly found together with mucosal pathoses including rhinosinusitis.<sup>52</sup>

Post nasal drip is where mucus drains onto the dorsal tongue via the nasopharynx.<sup>53</sup> This is related to allergic rhinitis, however, the existence of post-nasal drip as a clinical entity is disputed as this occurs in health and there is no agreed definition or pathologic changes.<sup>54</sup> Mucus stagnation provides a proteinaceous medium for more bacterial putrefaction, but the relationship between halitosis and post-nasal drip has not been formally investigated.

Obstructive nasal pathology causes mouthbreathing, possibly resulting in xerostomia and halitosis.<sup>13,55</sup>

Tonsillitis causes oedema and hypertrophy, which may obstruct orifices on tonsillar surface. This disrupts the cleansing flow of secretions, and desquamated epithelial and bacterial cells, extracellular matrix and food debris become trapped, leading to stagnation. Bacteria putrefy local substrate and release VOC and VSC, expressed on the breath as halitosis with a similar mechanism that operates on the tongue surface. Crypt debris may mineralise, similar to the transformation of dental plaque to dental calculus. These mineralised deposits are termed tonsilloliths (tonsil stones). The presence of tonsilloliths is strongly associated with abnormal VSC levels.<sup>46</sup> They are asymptotically present in up to 10% of the general population.<sup>56</sup> Anaerobic bacteria detected in tonsilloliths include *Eubacterium*, *Fusobacterium*, *Porphyromonas*, *Prevotella*, *Selenomonas* and *Tanarella spp.*, all associated with the production of VSCs.<sup>57</sup>

Odorous gases from the mouth or present in oronasal secretions can excite olfactory receptors and be perceived as halitosis,<sup>58</sup> even if no halitosis can be detected halitometrically. This is retronasal olfaction and is usually misdiagnosed.

'Airway reflux' describes gaseous or liquid gastric contents refluxing to the pharynx, oral cavity, nasal cavity, paranasal sinuses or even the middle ear,<sup>59</sup> and is sometimes said to be a cause of halitosis, however, there is little credible evidence for this mechanism.

Other respiratory tract causes of halitosis include: laryngitis, tracheitis, bronchitis, bronchiectasis, pneumonia, tuberculosis, nasal foreign bodies, rhinoliths, atrophic rhinitis (ozena), abscesses (peritonsillar, nasopharyngeal, lung), and carcinomas (nasal, sinuses, pharyngeal, lung).<sup>10,60-65</sup>

### Type 3 halitosis: gastroesophageal halitosis

Type 3 halitosis is leakage of odorant volatiles from the stomach via the oesophagus to the mouth and nose. This should be distinguished from volatiles in the GI tract being absorbed into the systemic circulation and exhaled (Type 4, blood-borne halitosis). A degree of gastroesophageal reflux is considered normal, occurring in almost all individuals several times per day.<sup>66</sup> In a study of 14 healthy individuals, 1.2 ml/10 min gas leakage from the stomach to the oesophagus while lying horizontal and 6.8 ml/10 min while sitting was demonstrated.<sup>67</sup> If odorous, this constitutes the physiologic part of gastroesophageal halitosis.

Pathologic level of gastroesophageal halitosis is said to occur due to i)

gastroesophageal reflux disease (GERD), ii) *Helicobacter pylori* related gastritis, or iii) other causes for example, gastrocolic fistulae, Zenker diverticulum and hypopharyngeal diverticulae.<sup>66</sup> Falcao *et al.* argued that certain GI disorders can cause taste disturbance. Taste receptor cells are associated with lingual papillae, but also present on the palate, epiglottis and upper oesophagus. Low intensity acid reflux can cause phantom taste sensations, which may manifest as subjective halitosis.<sup>16</sup>

Evidence for GERD-related halitosis is contradictory. Some studies report self-reported/subjective halitosis complaints are associated with GERD.<sup>68-71</sup> One study reported gastroesophageal pathology in less than 50% of patients complaining of halitosis,<sup>72</sup> while others report that GI disorders may account for up to 5% of objective halitosis complaints.<sup>31</sup> A systematic review investigated the relationship between GERD and halitosis (among other things). Three studies were included, and the authors concluded halitosis is a possible extra-oesophageal symptom of GERD,<sup>73</sup> however, two of these studies utilised questionnaires (that is, subjective halitosis). Yoo *et al.* report *H. pylori* infection correlated with elevated VSC in mouth and mucosal erosions,<sup>74</sup> posing halitosis as a potential biomarker to distinguish between erosive (200 ppb) and (75 ppb) non-erosive GERD.<sup>75</sup> Gas chromatography on gastric juice and biopsies in these subjects found resolved 7.5 ppm significantly higher H<sub>2</sub>S and expression of VSC-releasing enzymatic activity in the erosive group, and 0.5 ppm in the non-erosive group.<sup>74</sup> However, another study reported no significant difference in halitosis parameters when comparing erosive and nonerosive GERD.<sup>76</sup> Others have suggested the stomach rarely causes halitosis<sup>10</sup> and gastroscopy in halitosis patients is entirely unnecessary,<sup>12</sup> as the findings do not correlate with halitosis.<sup>77</sup> It has also been argued that there is no evidence that odorous substances are formed in the stomach.<sup>12</sup> Another study reported no statistically significant difference in the prevalence of halitosis symptoms between children with GERD and those without.<sup>78</sup>

*H. pylori* infection also has a controversial role. *H. pylori* possesses a strain-dependent ability to synthesise H<sub>2</sub>S and MM from combined cysteine-methionine substrate *in vitro*.<sup>79</sup> Elevated levels of both hydrogen cyanide and hydrogen nitrate were detected on the breath of *H. pylori* infected patients compared to healthy controls;<sup>80</sup> however, whether this represents Type 3 or Type 4 (blood-borne) halitosis is unknown.

Oral *H. pylori* colonisation without gastritis may cause Type 1 (oral) halitosis. PCR detected

Table 2 Example of aromatic gases exhaled in healthy individuals

Breath gas	Normal level (ppb)	Reference	Associated with
Ammonia	833 422-2390 688	25 96 97	Protein or amino acid metabolism, nitrogen metabolism
Acetone	477 661.3 462 293-870	25 98 26 96	Lipid metabolism
Methanol	461 32-1684	25 99	Abnormal gut flora, renal or pancreatic insufficiency, carbohydrate malabsorption
Ethanol	112 27-153 184 (7-18 age)	25 96 26	Bacterial overload in gut
Isoprene	106 117.6 212	25 98 100	Cholesterol synthesis
Propanol	18 20	25 26	Pancreatic insufficiency
Acetaldehyde	22 10 24	25 100 101	Alcohol metabolism
Butane	2.4	102	Protein oxidation/colonic bacteria
Alkanes C13-C20	1.5 x10 <sup>-10</sup> M/l	103	Oxidative stress
Dimethyl sulphide	0.2 nMol/l	12,104	Hepatic metabolism
Hydrogen*	<10 ppm	105	Carbohydrate metabolism in gut

\*Hydrogen is odourless, but its elevation >10 ppm in breath may indicate small intestinal bacterial overgrowth syndrome, ileocaecal valve syndrome, ileitis, or carbohydrate malabsorption/intolerance.<sup>106,107</sup> Along with methane, hydrogen is an indicator gas used in disaccharide malabsorption tests to detect intestinal gases exhaled in breath.<sup>108</sup> Odorous breath gases (Type 4 halitosis) are potentially present when breath hydrogen is elevated<sup>33</sup>

*H. pylori* in 6.4% (21/326) of saliva samples from non-dyspeptic individuals complaining of halitosis. *H. pylori* was associated with higher MM concentration.<sup>81</sup>

Improvements in halitosis (defined by various methodologies) following eradication therapy are reported.<sup>82-87</sup> Positive correlation between *H. pylori* and halitosis is reported by some studies,<sup>88-90</sup> however, some of these can be criticised for relying on self-reported halitosis rather than semi-objective breath analysis.<sup>91</sup> Others report no statistically significant correlation.<sup>69,77,91-93</sup>

This mechanism is rarely responsible for halitosis, but cannot presently be dismissed due to several studies that support the idea that GI disease may cause halitosis.

### Type 4 halitosis: blood-borne halitosis

Type 4 (blood-borne) halitosis is where volatile chemicals in the systemic circulation can transfer to exhaled breath during alveolar gas exchange and cause halitosis.<sup>94</sup>

Volatiles are endogenously produced, mostly by-products of biochemical metabolic processes.<sup>11</sup> The concentration of volatiles on the exhaled breath reflects their respective arterial concentrations.<sup>24</sup> Healthy subjects' breath contains 3,481 VOCs,<sup>95</sup>

constituting the physiologic aspect of Type 4 halitosis (Table 2).

Methylated or low carbon containing alkanes, cyclic hydrocarbons, alcohols and aldehydes has an especially pungent odour when they exceed specific odour thresholds for the individual or his/her social environment, constituting pathologic Type 4 halitosis. The threshold concentration for any given chemical depends on the change in intensity (odour strength) with concentration and the odour character. There is also interpersonal variation in emotional reactions to detected odour; some may react positively and others negatively.<sup>108</sup> A single volatile chemical can be perceived at lower concentrations than expected when it is combined in a mixture of thousands of VOC like the breath by interaction with other odorants and collective stimulation of olfactory receptors.

Artificial systems containing chemical sensor arrays for the detection of breath volatiles allow for profile readings of multiple compounds instead of single sensors for a single volatile.<sup>109</sup> This is more favourable as breath odours are not limited to a single or a handful of gasses describable according to their individual threshold levels. Rather, breath odours are 'olfactory spectra' of

breath. Every exhaled odorant gas should be suspected as potentially contributing, by varying degrees, to the overall perception of breath odour.

In pathologic Type 4 halitosis the concentrations and profile of exhaled gases is significantly different to those seen in health, depending on the pathology. Exhaled breath volatiles are reported in diabetes mellitus, sleep apnea, *H. pylori* infection, sickle cell disease, asthma, breast cancer, lung carcinoma, chronic obstructive pulmonary disease, cystic fibrosis, liver diseases, cirrhosis, uraemia, kidney failure and TMAU.<sup>24,94</sup>

Breath alkanes have a pungent odour and are elevated in intestinal inflammation,<sup>110</sup> for example, ulcerative colitis,<sup>111,112</sup> Crohn's disease,<sup>112</sup> in pulmonary tuberculosis,<sup>113</sup> schizophrenia,<sup>114</sup> pneumonia,<sup>115</sup> asbestos-related disorders,<sup>116</sup> stomach cancer,<sup>117</sup> and angina pectoris.<sup>118</sup> Pregnant females or pre-eclampsia patients have a specific breath gas profile, including undecane, 6-methyltridecane, 2-methylpentane, 5-methyltetradecane and 2-methylnonane.<sup>119</sup> DMS, acetone, 2-butanone and 2-pentanone are reported in liver failure, including cirrhosis.<sup>27</sup>

The 'fetor hepaticus' of hepatic failure is largely caused by DMS, not ammonia.<sup>28</sup> Elevated blood DMS ('dimethylsulphidemia'),<sup>28</sup> was reported to be responsible for the majority of cases of blood borne halitosis.<sup>12</sup>

Body odour may accompany Type 4 halitosis as the same volatiles are also excreted during perspiration. This is sometimes termed blood-borne body odour and halitosis. An example is TMAU, a rare condition, classically characterised by fish odour in urine, sweat and breath.

When odorous chemical in blood circulation exceeds a critical level then it is secreted to breath, urine, tear, saliva and sweat. In such conditions body odour appears. In other circumstances, breath odour (Type 4 halitosis) is detected without body odour.

Another potential blood-borne mechanism may contribute to a halitosis complaint when blood-borne odorants stimulate olfactory receptors via their blood supply.<sup>16,120</sup> Strong olfactory receptor responses can be triggered by intravascular injection of odorants in tracheotomised animals. Such odour perceptions are not occurring by the normal air-borne route, so there may not be measurable halitosis.

### Type 5 halitosis: subjective halitosis

Subjective halitosis is a halitosis complaint without objective confirmation of halitosis by others or halitometer readings. Type 5 halitosis can be misdiagnosed if there are measurement errors or transient symptoms.

It can be considered normal for even mentally healthy individuals to worry occasionally about to be having halitosis.<sup>121</sup> Such halitosis concern can be rationally dismissed by most healthy people who have a degree of psychological resilience that is capable of compensating for stressors. This normal level of concern for halitosis constitutes the 'physiologic' aspect of Type 5 halitosis.

Pathologic subjective halitosis can be categorised as psychologic or neurologic.

### Psychologic causes

Psychologic factors can cause subjective halitosis. This is termed monosymptomatic hypochondriacal psychosis,<sup>16</sup> a type of obsessive-compulsive spectrum disorder,<sup>121</sup> or olfactory reference syndrome (ORS). Seventy-five percent of ORS patients present with halitosis complaints,<sup>122</sup> but obsession over other non-existent body odours, often in combination, are included. Others' behaviour (for example, opening windows, sniffing, touching noses *etc*) is misinterpreted as evidence of halitosis. Employment loss, divorce or suicidal ideation are reported.<sup>123</sup> 'Doctor shopping' to find clinicians to treat the non-existent odour may occur. However, some report that TMAU or other genuine odour symptoms can be misdiagnosed as ORS.<sup>124</sup>

It may be the case that the previously black and white thinking of objective halitosis on the one hand and psychologic halitosis on the other is an oversimplification. Instead, it might be more accurate to consider a spectrum, with entirely subjective halitosis at one extreme and entirely objective halitosis with no psychologic concern at the other. Most patients will fall somewhere between these two points.

When objective halitosis has not been treated it may cause the patient distress or social isolation and eventually over-concern about halitosis may develop. Even after the odour is reduced to physiologic levels, the negative psychosocial sequelae may persist, making these cases difficult to treat. Conversely, oversensitivity to physiologic odour may be the basis of a subjective halitosis with no history of objective halitosis.

### Neurogenic causes

Traditionally, subjective halitosis complaints are attributed to psychologic factors, but at least some are neurologic. Nearly 200 disorders can cause chemosensory dysfunction (CSD).<sup>16</sup> Dysosmia (disordered olfaction including parosmia and phantosmia) and dysgeusia (disordered gustation) present extensive differential diagnoses.

Olfaction and gustation are intimately interlinked at the neuronal level in the brain. The definition of subjective halitosis (pseudo-halitosis) has been broadened: 'the perception of an alteration in the quality of expired odour air, a symptom perceived only by the patient.'<sup>16</sup> Many patients fail to distinguish between bad taste and bad odour. Gustatory stimuli may influence orthonasal and retronasal odorant perception.<sup>58</sup>

Side effects of medication, hypothyroidism, hyposalivation (another extensive differential), nutrient deficiency (zinc, copper, iron, and vitamins A and B12), trauma and tumours involving the olfactory centre in the brain, or nerve damage (glossopharyngeal, vagus, chorda tympani, olfactory), neurodegenerative diseases (Parkinson's, Alzheimer's and Huntington's disease), environmental pollutants (for example, smoking), drug abuse, certain oral hygiene products (for example, mouthwashes) and certain foodstuffs can all be potentially involved in subjective halitosis complaints by various mechanisms.<sup>16,125</sup> As described previously, diabetes mellitus, GERD and blood-borne stimulation of taste and smell receptors via the blood circulation may also contribute to subjective halitosis.<sup>16,126</sup>

## NEW TERMINOLOGY

### Unhelpful terms no longer needed:

- Many of the confusing array of synonyms used to describe a psychologic, subjective halitosis complaint (which would fall within Type 5 halitosis) are unneeded, including pseudo-halitosis, non-genuine halitosis, delusional halitosis, olfactory obsession, psico-olfactory sensitivity, olfactory depression, halitosis anxiety and imaginary halitosis
- Subjective, descriptive terms such as sulphurous, ammoniacal, faecal, fishy or similar should be discontinued since they invite misunderstanding.

### Useful terms that are retained:

- Objective halitosis refers to any combination of Types 1-4, but should not refer to Type 1 (oral) halitosis exclusively
- Morning breath is a temporarily increased physiologic halitosis during sleep and disappears soon after waking.<sup>127</sup> Xerostomia is largely responsible,<sup>128</sup> resulting from diminished salivary and respiratory secretion during sleep, especially when the mouth remains open. Proteinaceous substrates in saliva allows for microbial action, and release of VSC and other volatiles, thereby enhancing

Type 1 and 2 halitosis. Increased breath ammonia, acetone,<sup>97,129</sup> and isoprene,<sup>127</sup> occur after overnight fasting. Intestinal gas builds up in the colon during sleep,<sup>130</sup> possibly due to immobility and microbial fermentation of intestinal contents. More Type 4 halitosis might result, or possibly, more gas leakage from the gastroesophageal valve (that is, Type 3). All the above mechanisms may operate during sleep. The resultant halitosis upon waking can be termed morning breath, in reality an enhanced form of Type 0 halitosis

- Psychosomatic halitosis should be retained, but the term should not be misused. Some hypothesise that anxiety enhances oral VSC production.<sup>131</sup> This mechanism is correctly termed psychosomatic, since a physical symptom is being influenced by psychologic factors. This is the uniquely correct usage of the term 'psychosomatic halitosis', rather than previous meanings (see 'Previous terminology')
- Self-halitosis has been used to describe a lack of objective halitosis even though the patient believes themselves to have halitosis,<sup>32</sup> but it is better used to define endogenously produced, self-perceived odour, which is not a detectable odour to others. By true description, self-halitosis appears in three forms: retronasal olfaction, olfactory receptor responses triggered by blood-borne odorants, and phantom tastes/odours
- Halitophobia should be retained with correct meaning. It refers to 'fear of having halitosis' but not 'untreated halitosis'.

### New terms

- Exogenous odour results from consumption of aromatic foodstuffs (for example, garlic, onion, spicy foods), beverages (for example, alcohol) or tobacco. Exogenous volatiles may be released transiently from residues of food or drink in the mouth, or released unchanged via the blood-borne mechanism after being absorbed. Such odours are distinguished from pathologic halitosis, for example, garlic smells like garlic. The terms garlic odour, spice odour, *etc* seem suitable. Dietary or temporary halitosis are also terms that could be argued to be useful
- Halitosis is an endogenous odour because it is produced in the body.

## DISCUSSION

The new definition places less importance on organoleptic examination and single

occasion halitometric reading, and instead places more emphasis on the declarations of the patient and his/her social environment. The reasoning for this follows.

### Organoleptic examination

Organoleptic measurement is carried out by smelling the patient's breath then scoring the level of halitosis.<sup>7</sup> However, the examiner does not smell a pure sample of mouth air, but rather a mixture of mouth air and alveolar air. The organoleptic examination does not distinguish between these, only subjectively assesses the overall odour level.

The perception of odorants depends upon several factors, including constant fluctuations in the clinician's individual threshold level for that specific odour, what was last smelled before the examination, the concentration and volatility of the molecules themselves, room temperature (gases are less volatile in lower temperatures), humidity of exhaled breath, how strongly the breath is blown into the examiner's nose (less forcefully expired breath will consist of less volume of air, and less odorant molecules will be carried to the examiner's olfactory epithelia), and lastly the examiner's concentration at that moment. All these parameters vary from one hour to the next and from one individual to the next, making this a subjective measure that does not reflect the actual level of odour. It can be suggested that self-applied organoleptic scoring (self-assessment) should be evaluated to monitorise prognosis.

Organoleptic examination is problematic,<sup>132</sup> and objectionable to both dentists and to patients. Dislike or shame is experienced by 50% of patients with this examination (n = 283).<sup>133</sup> Some use a privacy screen to prevent the patient from seeing the examiner during the examination.<sup>7</sup> Examiners find it repulsive to smell a halitosis patient's breath.

Self-detection of halitosis correlated positively with actual halitosis only when subjects smelt their own saliva isolated from their mouth. Other methods did not correlate.<sup>134</sup> Another study reported less correlation between self-detection of halitosis and clinical findings. The sensitivity and specificity of self-perceived oral malodour were 47.2% and 59.2%, respectively.<sup>135</sup> The same author later compared 252 halitosis patients' self-estimation, organoleptic and halitometric results and found that self-estimated corresponded significantly with clinical oral malodour.<sup>136</sup>

### Halimeters

Gas chromatography (GC), alone or combined with mass spectrometry (MS), is most frequently utilised for highly sensitive VSC

**Table 3** Variation in the 'halitosis threshold' reported in the literature

Halitosis threshold (VSC ppb) *organoleptic score	Reference
75	156
100 (2*)	7, 31, 157, 158
110	12
125	40
150	14, 35, 94, 159
250 (3*)	81, 160, 161
Total: VSC 250 H <sub>2</sub> S, CH <sub>3</sub> SH, (CH <sub>3</sub> ) <sub>2</sub> S: 150, 50, 20 respectively (3*)	81

detection (1-10 ppb). Nevertheless, routine application of these clinically is impractical given the expense and complexity, and the expertise required.<sup>94</sup> More practical methods utilise colorimetric hydrogen sulphide sensors engineered both as an optical fibre, capable of measuring reflectance change of an immobilized reagent,<sup>137</sup> and as thin reactive films of chromophores.<sup>138</sup> A bio-electronic nose capable of detecting the oxygen consumption induced by an enzymatic reaction with methyl sulphide has also been developed.<sup>139</sup> The Halimeter<sup>140</sup> contains an electrochemical sensor for VSC. The semiconductor gas sensors Breathron,<sup>141</sup> constructed as a zinc oxide film with specificity to hydrogen sulphide and mercaptans.<sup>142</sup> The GC-based OralChroma,<sup>143</sup> is portable equipment capable of determining combined H<sub>2</sub>S, MM and DMS levels, with a 10 min response time and a detection limit of a few ppb. Twin Breasor,<sup>144</sup> Diamond Probe/Perio 2000,<sup>145</sup> Cyranose 320,<sup>146</sup> and B/B Checker,<sup>147</sup> are portable devices for detecting several gases including VSC and other odorous gases in mouth or breath air.<sup>148,149</sup> Their accuracy is poor compared to GC and MS. They cannot distinguish one odour from another, and they have difficulty distinguishing individual compounds from the family of VSC.<sup>132</sup>

Almost all halitosis researchers and specialists use portable sulphide monitors (for example, Halimeter) to detect oral VSC.<sup>14</sup> Good correlation exists between Halimeter readings and VSC concentration,<sup>35</sup> and sulphur-producing bacteria levels.<sup>150</sup> However, Halimeter readings are imprecise and misdiagnosis may result.<sup>151</sup> The Halimeter has biexponential response to a constant concentration of VSC. Rapid (peak) and slow (plateau) responses differed. The total VSC in air samples was 2.7 times greater than at its peak concentration, but its plateau phase measurement is 25% greater than the actual concentration. A modified protocol measuring plateau instead of peak values is available, yielding more favorable correlation with the actual level of VSC.<sup>152</sup>

In order to investigate the Halimeter's ability to distinguish between VSC and other gases, having calibrated the Halimeter to ambient air, the aspirating tube was inserted into the headspace of some 250 ml commercial juice cartons immediately after opening. The Halimeter readings for apricot, apple, peach, cherry juices, buttermilk, soda, were 114, 352, 91, 48, 39, 47 ppb VSC respectively. In a similar experiment, the Halimeter reported VSC as if H<sub>2</sub>S is emitted from various flowers: daffodil, rose, jasmine were 255, 42, 73 ppb while 104 ppb was read near a sump, and 417 ppb near hand soap. When using another gas detector in the same conditions, all these flowers read with different percentages of VOC, not VSC.<sup>153</sup> Such simple experiments show that the Halimeter seems to confuse VSC with other odorants, and may not be selective enough for halitosis. The OralChroma gives more comprehensive VSC level readings than the Halimeter,<sup>41</sup> but it shares the VSC exclusivity limitation and therefore cannot fully determine the actual level of breath odour due to potential minor contributions from non-VSC gases.

New gas detectors capable of detecting sulphur and nitrogen containing gases, as well as VOCs should be developed for use in halitosis detection. There are industrial, portable gas detectors that are capable of detect more than four gas groups including VSC, NH<sub>3</sub>, or VOC that could potentially be utilised at one reading. A sensor system for monitoring the simple gases H<sub>2</sub>, CO, H<sub>2</sub>S, NH<sub>3</sub>, VOC and ethanol,<sup>154</sup> and breath test kits including instruments to detect breath H<sub>2</sub> and methane are available.<sup>155</sup>

### Perturbation on threshold of halitosis

There is no consensus regarding what VSC reading corresponds to clinically present halitosis (Table 3).

Besides these data, some describe ranges of VSC readings, eg: 0-40, healthy; 41-60, physiologic; 61-80, slight; 81-110, moderate;

111–140, severe; over 141, very strong.<sup>162</sup>

VSC thresholds should be revisited to improve clinical utility.<sup>163</sup> According to the new concepts described in this paper, there is no need to establish any precise VSC level that constitutes a halitosis diagnosis. Any patient complaining of halitosis is at least Type 5, even if objective halitosis is not diagnosed. Treatment should be targeted reducing pathologic halitosis to physiologic halitosis. Setting the goal at zero odour is unrealistic and arguably impossible.

There are three reasons to restrict the use of halitometers. Firstly, since baseline mouth air VSC concentrations fluctuate throughout day,<sup>151</sup> halitometric reading at any particular time may not be representative. For this reason, multiple halitometric examinations carried out at different times throughout the day may be more representative compared to a single occasion in the dental clinic. Or cysteine challenge,<sup>164</sup> should be applied to decide optimal VSC level of that individual.

Secondly, popular, portable halitometers are simply sulphide detectors, capable of detecting only VSC. However, nonsulphurous gases are also present in the mouth or breath, albeit in a lesser concentration than VSC. Halitometers are poor at distinguishing one odour from another. For example, in TMAU, the breath could be malodorous due to the presence of TMA and VSC levels may be under the normal range in such patients. Thus, examiners may misdiagnose some objective halitosis cases as if subjective halitosis by relying entirely on the specificity of halitometers.

Thirdly, there is no scientifically accepted quantitative threshold between physiologic odour and pathologic halitosis.

- Quirynen M, Van den Velde S, Vandekerckhove B, Dadamio J. Oral Malodor. In Newman M G, Takei H H, Klokkevold P R, Carranza F A (eds) *Carranza's clinical periodontology*. 11th ed. pp 331–338. St. Louis, Mo: Elsevier/Saunders, 2012.
- Lindhe J, Lang N P, Karring T (eds) *Clinical periodontology and implant dentistry*. 5th ed. Oxford: Blackwell Munksgaard, 2008.
- Cortelli J R, Barbosa M D, Westphal M A. Halitosis: a review of associated factors and therapeutic approach. *Braz Oral Res* 2008; **22**(Suppl 1): 44–54.
- Outhouse T L, Al-Alawi R, Fedorowicz Z, Keenan J V. Tongue scraping for treating halitosis. *Cochrane Database Syst Rev* 2006; CD005519.
- Fedorowicz Z, Aljufairi H, Nasser M, Outhouse T L, Pedrazzi V. Mouthrinses for the treatment of halitosis. *Cochrane Database Syst Rev* 2008; CD006701.
- Miyazaki H, Arai M, Okamura K, Kawaguchi Y, Toyofuku A, Hoshi K, Yaegaki K. Tentative classification of halitosis and its treatment needs. *Niigata Dental Journal* 1999; **32**: 7–11.
- Yaegaki K, Coil J M. Examination, classification, and treatment of halitosis; clinical perspectives. *J Can Dent Assoc* 2000; **66**: 257–261.
- Murata T, Yamaga T, Iida T, Miyazaki H, Yaegaki K. Classification and examination of halitosis. *Int Dent J* 2002; **52**(Suppl 3): 181–186.
- Yaegaki K, Coil J M. Genuine halitosis, pseudo-halitosis, and halitophobia: classification, diagnosis, and treatment. *Compend Contin Educ Dent* 2000; **21**: 880–886, 888–889.
- Tangerman A, Winkel E G. Extra-oral halitosis: an overview. *J Breath Res* 2010; **4**: 017003.
- Tangerman A. Halitosis in medicine: a review. *Int Dent J* 2002; **52**(Suppl 3): 201–206.
- Tangerman A, Winkel E G. Intra- and extra-oral halitosis: finding of a new form of extra-oral blood-borne halitosis caused by dimethyl sulphide. *J Clin Periodontol* 2007; **34**: 748–755.
- Motta L J, Bachiega J C, Guedes C C, Laranja L T, Bussadori S K. Association between halitosis and mouth breathing in children. *Clinics (Sao Paulo)* 2011; **66**: 939–942.
- Richter J L. Diagnosis and treatment of halitosis. *Compend Contin Educ Dent* 1996; **17**: 370–372, 374–376.
- Iwu C O, Akpata O. Delusional halitosis. Review of the literature and analysis of 32 cases. *Br Dent J* 1990; **168**: 294–296.
- Falcão D P, Vieira C N, Batista de Amorim R F. Breaking paradigms: a new definition for halitosis in the context of pseudo-halitosis and halitophobia. *J Breath Res* 2012; **6**: 017105.
- Seemann R, Bizhang M, Djamchidi C, Kage A, Nachnani S. The proportion of pseudo-halitosis patients in a multidisciplinary breath malodour consultation. *Int Dent J* 2006; **56**: 77–81.
- Videbech T. Chronic olfactory paranoid syndromes. A contribution to the psychopathology of the sense of smell. *Acta Psychiatr Scand* 1966; **42**: 183–213.
- Takahashi T. A social club spontaneously formed by ex-patients who had suffered from anthropophobia (Taijin kyofu (sho)). *Int J Soc Psychiatry* 1975; **21**: 137–140.
- Rosenberg M, Leib E. Introduction. In Rosenberg M (ed). *Bad breath: research perspectives*. 2nd ed. pp 9–13. Tel Aviv: Ramot Publishing, Tel Aviv University; 1997.
- Lochner C, Stein D J. Olfactory reference syndrome: diagnostic criteria and differential diagnosis. *J Postgrad Med* 2003; **49**: 328–331.
- Phillips K A. How to help patients with olfactory reference syndrome. Delusion of body odour causes shame, social isolation. *The Journal of Family Practice* 2007; **6**: 1.
- Zaitu T, Ueno M, Shinada K, Wright F A, Kawaguchi Y. Social anxiety disorder in genuine halitosis patients. *Health Qual Life Outcomes* 2011; **9**: 94.
- Whittle C L, Fakhrazadeh S, Eades J, Preti G. Human breath odours and their use in diagnosis. *Ann N Y Acad Sci* 2007; **1098**: 252–266.
- Smith D, Turner C, Spaněl P. Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. *J Breath Res* 2007; **1**: 014004.
- Enderby B, Lenney W, Brady M, Emmett C, Spaněl P, Smith D. Concentrations of some metabolites in the breath of healthy children aged 7–18 years measured using selected ion flow tube mass spectrometry (SIFT-MS). *J Breath Res* 2009; **3**: 036001.
- Van den Velde S, Nevens F, Van Hee P, van Steenberghe D, Quirynen M. GC-MS analysis of breath odour compounds in liver patients. *J Chromatogr B Analyt Technol Biomed Life Sci* 2008; **875**: 344–348.
- Harvey-Woodworth C N. Dimethylsulphidemia: the significance of dimethyl sulphide in extra-oral, blood borne halitosis. *Br Dent J* 2013; **214**: E20.
- Coulthwaite L, Verran J. Development of an *in vitro* denture plaque biofilm to model denture malodour. *J Breath Res* 2008; **2**: 017004.
- Davies S, Spanel P, Smith D. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. *Kidney Int* 1997; **52**: 223–228.
- Bollen C M, Beikler T. Halitosis: the multidisciplinary approach. *Int J Oral Sci* 2012; **4**: 55–63.
- Yaegaki K, Coil J M. Clinical dilemmas posed by patients with psychosomatic halitosis. *Quintessence Int* 1999; **18**: 328–333.
- Aydin M. Halitosis. In Aydin M, Misirligil A (eds). *Oral microbiology*. pp 97–104. Ankara: MN Medical & Nobel, 2012.
- Van den Velde S, van Steenberghe D, Van Hee P, Quirynen M. Detection of odorous compounds in breath. *J Dent Res* 2009; **88**: 285–289.
- Phillips M, Cataneo R N, Greenberg J, Munawar M, Nachnani S, Samtani S. Pilot study of a breath test for volatile organic compounds associated with oral malodour: evidence for the role of oxidative stress. *Oral Dis* 2005; **11**(Suppl 1): 32–34.
- Dadamio J, Van Tornout M, Van den Velde S, Federico R, Dekeyser C, Quirynen M. A novel and visual test for oral malodour: first observations. *J Breath Res* 2011; **5**: 046003.
- Hartley M G, El-Maaytah M A, McKenzie C, Greenman J. The tongue microbiota of low odour and malodorous individuals. *Micro Ecol Health Dis* 2009; **9**: 215–223.
- Hess J, Greenman J, Duffield J. Modelling oral malodour from a tongue biofilm. *J Breath Res* 2008; **2**: 017003.
- Aydin M. Anaerobic bacteria and anaerobism; Microbial biofilms and aerosols. In Cengiz T, Misirligil A, Aydin M (eds) *Microbiology in dentistry and medicine*. pp 175–180; 569–576. Ankara: Güneş Medical, 2004.
- Kozeowski Z, Mikeaszewska B B, Konopka T, Kawa Z D, Lewczyk E. Using a Halitometer to verify the symptoms of halitosis. *Adv Clin Exp Med* 2007; **16**: 411–416.
- Salako N O, Philip L. Comparison of the use of the Halimeter and the Oral Chroma™ in the assessment of the ability of common cultivable oral anaerobic bacteria to produce malodorous volatile sulphur compounds from cysteine and methionine. *Med Princ Pract* 2011; **20**: 75–79.
- Aydin M. *Otorigenic bacteria in halitosis*. Istanbul: Nobel medical, 2008.
- Zürcher A, Filippi A. Findings, diagnoses and results of a halitosis clinic over a seven year period. *Schweiz Monatsschr Zahnmed* 2012; **122**: 205–216.
- Delanghe G, Bollen C, Desloovere C. Halitosis-foetor ex ore. *Laryngorhinootologie* 1999; **78**: 521–524.
- Quirynen M, Dadamio J, Van den Velde S *et al*. Characteristics of 2000 patients who visited a halitosis clinic. *J Clin Periodontol* 2009; **36**: 970–975.
- Bollen C M, Rompen E H, Demanez JP. Halitosis: a multidisciplinary problem. *Rev Med Liege* 1999; **54**: 32–36.
- Fletcher S M, Blair P A. Chronic halitosis from tonsilloliths: a common aetiology. *J La State Med Soc* 1988; **140**: 7–9.
- Lanza D C. Diagnosis of chronic rhinosinusitis. *Ann Otol Rhinol Laryngol Suppl* 2004; **193**: 10–14.
- Bunzen D L, Campos A, Leão F S, Morais A, Sperandio F, Caldas Neto S. Efficacy of functional endoscopic sinus surgery for symptoms in chronic rhinosinusitis with or without polyposis. *Braz J Otorhinolaryngol* 2006; **72**: 242–246.
- Tatli M M, San I, Karaoğlanoglu M. Paranasal sinus computed tomographic findings of children with chronic cough. *Int J Paediatr Otorhinolaryngol* 2001; **60**: 213–217.
- Schlosser R J, Harvey R J. Diagnosis of chronic rhinosinusitis. In Thaler E R, Kennedy D W (eds) *Rhinosinusitis*. pp 43. New York: Springer LLC, 2008.
- Yücel A, Dereköy F S, Yılmaz M D, Altuntaş A. Effects of sinonasal anatomical variations on paranasal sinus infections. *The Medical Journal of Kocatepe* 2004; **5**: 43–47.
- Amir E, Shimonov R, Rosenberg M. Halitosis in children. *J Paediatr* 1999; **134**: 338–343.
- Morice A H. Post-nasal drip syndrome—a symptom to be sniffed at? *Pulm Pharmacol Ther* 2004; **17**: 343–345.
- Ng D K, Chow P Y, Kwok K L. Halitosis and the nose. *Hong Kong Med J* 2005; **11**: 71–72.
- Stoodley P, Debeer D, Longwell M *et al*. Tonsillolith: not just a stone but a living biofilm. *Otolaryngol Head Neck Surg* 2009; **141**: 316–321.
- Tsuneishi M, Yamamoto T, Koikeguchi S, Tamaki N, Fukui K, Watanabe T. Composition of the bacterial flora in tonsilloliths. *Microbes Infect* 2006; **8**: 2384–9.
- Welge-Lüssen A, Husner A, Wolfensberger M, Hummel T. Influence of simultaneous gustatory stimuli on orthonasal and retronasal olfaction. *Neurosci Lett* 2009; **454**: 124–128.



59. Koufman J A, Aviv J E, Casiano R R, Shaw G Y. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. *Otolaryngol Head Neck Surg* 2002; **127**: 32–35.
60. Brent A. Odour – unusual. In Fleisher G R, Ludwig S (eds) Textbook of paediatric emergency medicine 6th ed. pp 402–405. Lippincott Williams & Wilkins, 2010.
61. Sethi S, Nanda R, Chakraborty T. Clinical application of volatile organic compound analysis for detecting infectious diseases. *Clin Microbiol Rev* 2013; **26**: 462–475.
62. Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. *J Biochem* 2011; **150**: 257–266.
63. Brehmer D, Riemann R. The rhinolith—a possible differential diagnosis of a unilateral nasal obstruction. *Case Rep Med* 2010; **2010**: 845671.
64. de Shazo R D, Stringer S P. Atrophic rhinosinitis: progress toward explanation of an unsolved medical mystery. *Curr Opin Allergy Clin Immunol* 2011; **11**: 1–7.
65. Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. *Cochrane Database Syst Rev* 2012; **2**: CD008280.
66. Hirano I, Kahrihas P J, Pandolfino J E, Richter J E, Soll A H, Graham D Y. In Yamada T, Alpers D H (eds) *Textbook of gastroenterology*, 5th ed. pp. 732, 742, 772, 951. Chichester: Blackwell Publishing 2009.
67. Wyman J B, Dent J, Heddl R, Dodds W J, Toouli J, Downton J. Control of belching by the lower oesophageal sphincter. *Eur J Gastroenterol Hepatol* 1990; **31**: 639–646.
68. Di Fede O, Di Liberto C, Occhipinti G *et al*. Oral manifestations in patients with gastro-oesophageal reflux disease: a single-centre case-control study. *J Oral Pathol Med* 2008; **37**: 336–340.
69. Struch F, Schwahn C, Wallaschofski H *et al*. Self-reported halitosis and gastro-oesophageal reflux disease in the general population. *J Gen Intern Med* 2008; **23**: 260–266.
70. Moshkowitz M, Horowitz N, Leshno M, Halpern Z. Halitosis and gastroesophageal reflux disease: a possible association. *Oral Dis* 2007; **13**: 581–585.
71. Saberi-Firoozi M, Khademolhosseini F, Yousefi M, Mehrabani D, Zare N, Heydari S T. Risk factors of gastroesophageal reflux disease in Shiraz, southern Iran. *World J Gastroenterol* 2007; **13**: 5, 486–491.
72. Kinberg S, Stein M, Zion N, Shaoul R. The gastrointestinal aspects of halitosis. *Can J Gastroenterol* 2010; **24**: 552–556.
73. Marsicano J A, de Moura-Grec P G, Bonato R C, Sales-Peres M de C, Sales-Peres A, Sales-Peres S H. Gastroesophageal reflux, dental erosion, and halitosis in epidemiological surveys: a systematic review. *Eur J Gastroenterol Hepatol* 2013; **25**: 135–141.
74. Yoo S H, Jung H S, Sohn W S *et al*. Volatile sulphur compounds as a predictor for esophagogastrroduodenal mucosal injury. *Gut Liver* 2008; **2**: 113–118.
75. Kim J G, Kim Y J, Yoo S H *et al*. Halimeter ppb levels as the predictor of erosive gastroesophageal reflux disease. *Gut Liver* 2010; **4**: 320–325.
76. Kislig K, Wilder-Smith C H, Bornstein M M, Lussi A, Seemann R. Halitosis and tongue coating in patients with erosive gastroesophageal reflux disease versus nonerosive gastroesophageal reflux disease. *Clin Oral Invest* 2013; **17**: 159–165.
77. Tas A, Köklü S, Yüksel I, Başar O, Akbal E, Cimbeke A. No significant association between halitosis and upper gastrointestinal endoscopic findings: a prospective study. *Chin Med J (Engl)* 2011; **124**: 3, 707–710.
78. Carr M M, Nguyen A, Nagy M, Poje C, Pizzuto M, Brodsky L. Clinical presentation as a guide to the identification of GERD in children. *Int J Paediatr Otorhinolaryngol* 2000; **54**: 27–32.
79. Lee H, Kho H S, Chung J W, Chung S C, Kim Y K. Volatile sulphur compounds produced by *Helicobacter pylori*. *J Clin Gastroenterol* 2006; **40**: 421–426.
80. Lechner M, Karlseder A, Niederseer D *et al*. H. pylori infection increases levels of exhaled nitrate. *Helicobacter* 2005; **10**: 385–390.
81. Suzuki N, Yoneda M, Naito T *et al*. Detection of *Helicobacter pylori* DNA in the saliva of patients complaining of halitosis. *J Med Microbiol* 2008; **57**: 1553–1559.
82. Katsinelos P, Tziomalos K, Chatzimavroudis G *et al*. Eradication therapy in *Helicobacter pylori*-positive patients with halitosis: long-term outcome. *Med Princ Pract* 2007; **16**: 119–123.
83. Serin E, Gumurdulu Y, Kayaselcuk F, Ozer B, Yilmaz U, Boyacioglu S. Halitosis in patients with *Helicobacter pylori*-positive non-ulcer dyspepsia: an indication for eradication therapy? *Eur J Intern Med* 2003; **14**: 45–48.
84. Shashidhar H, Peters J, Lin C H, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for paediatric *Helicobacter pylori* infection. *J Paediatr Gastroenterol Nutr* 2000; **30**: 276–282.
85. Gasbarrini A, Ojetti V, Vitocco D *et al*. Insulin-dependent diabetes mellitus affects eradication rate of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1999; **11**: 713–716.
86. Ierardi E, Amoroso A, La Notte T *et al*. Halitosis and *Helicobacter pylori*: a possible relationship. *Dig Dis Sci* 1998; **43**: 2733–2737.
87. Tiomny E, Arber N, Moshkowitz M, Peled Y, Gilat T. Halitosis and *Helicobacter pylori*. A possible link? *J Clin Gastroenterol* 1992; **15**: 236–237.
88. Chen X, Tao D Y, Li Q, Feng X P. The relationship of halitosis and *Helicobacter pylori*. *Shanghai Kou Qiang Yi Xue* 2007; **16**: 236–238.
89. Adler I, Denninghoff V C, Alvarez M I, Avagnina A, Yoshida R, Elsner B. *Helicobacter pylori* associated with glossitis and halitosis. *Helicobacter* 2005; **10**: 312–317.
90. Li X B, Liu W Z, Ge Z Z *et al*. Analysis of clinical characteristics of dyspeptic symptoms in Shanghai patients. *Chin J Dig Dis* 2005; **6**: 62–67.
91. Tangerman A, Winkel E G, de Laat L, van Oijen A H, de Boer W A. Halitosis and *Helicobacter pylori* infection. *J Breath Res* 2012; **6**: 017102.
92. Dore M P, Fanciulli G, Tomasi P A *et al*. Gastrointestinal symptoms and *Helicobacter pylori* infection in school-age children residing in Porto Torres, Sardinia, Italy. *Helicobacter* 2012; **17**: 369–373.
93. Imanzadeh F, Imanzadeh A, Sayyari A A, Yagenah M, Javaherizadeh H, Hatamian B. *Helicobacter pylori* infection; in cases with and without subjective halitosis. *Professional Med J* 2010; **17**: 543–545.
94. Ciaffoni L, Peverall R, Ritchie G A. Laser spectroscopy on volatile sulphur compounds: possibilities for breath analysis. *J Breath Res* 2011; **5**: 024002.
95. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo R N. Variation in volatile organic compounds in the breath of normal humans. *J Chromatogr B Biomed Sci Appl* 1999; **729**: 75–88.
96. Diskin A M, Spanel P, Smith D. Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. *Physiol Meas* 2003; **24**: 107–119.
97. Schmidt F M, Vaitinen O, Metsälä M *et al*. Ammonia in breath and emitted from skin. *J Breath Res* 2013; **7**: 017109.
98. Wang T, Pysanenko A, Dryahina K, Spanel P, Smith D. Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. *J Breath Res* 2008; **2**: 037013.
99. Turner C, Spanel P, Smith D. A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. *Physiol Meas* 2006; **27**: 637–648.
100. Turner C, Parekh B, Walton C, Spanel P, Smith D, Evans M. An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. *Rapid Commun Mass Spectrom* 2008; **22**: 526–532.
101. Turner C, Spanel P, Smith D. A longitudinal study of ethanol and acetaldehyde in the exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry. *Rapid Commun Mass Spectrom* 2006; **20**: 61–68.
102. Kharitonov S A, Barnes P J. Biomarkers of some pulmonary diseases in exhaled breath. *Biomarkers* 2002; **7**: 1–32.
103. Phillips M, Greenberg J, Cataneo R N. Effect of age on the profile of alkanes in normal human breath. *Free Radic Res* 2000; **33**: 57–63.
104. Blom H J, Tangerman A. Methanethiol metabolism in whole blood. *J Lab Clin Med* 1988; **111**: 606–610.
105. Hamilton L H. *Breath tests and gastroenterology*. 2nd ed. Milwaukee: Quintron Co, 1998.
106. Probert C S, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. Volatile organic compounds as diagnostic biomarkers in gastrointestinal and liver diseases. *J Gastrointest Liver Dis* 2009; **18**: 337–343.
107. Phillips M. Breath tests in medicine. *Sci Am* 1992; **267**: 74–79.
108. Leonardos G, Kendall D, Barnard N. Odour threshold determinations of 53 odorant chemicals. *J Air Waste Ma* 1969; **19**.
109. Bofan M, Mores N, Baron M *et al*. Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. *J Breath Res* 2013; **7**: 017103.
110. Kokoszka J, Nelson R L, Swedler W I, Skosey J, Abcarian H. Determination of inflammatory bowel disease activity by breath pentane analysis. *Dis Colon Rectum* 1993; **36**: 597–601.
111. Sedghi S, Keshavarzian A, Klamut M, Eizhamer D, Zarleng E J. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. *Am J Gastroenterol* 1994; **89**: 2217–2221.
112. Pelli M A, Trovarelli G, Capodicasa E, De Medio G E, Bassotti G. Breath alkanes determination in ulcerative colitis and Crohn's disease. *Dis Colon Rectum* 1999; **42**: 71–76.
113. Phillips M, Dalay V B, Bothamley G *et al*. Breath biomarkers of active pulmonary tuberculosis. *Tuberculosis* 2010; **90**: 145–151.
114. Phillips M, Erickson G A, Sabas M, Smith J P, Greenberg J. Volatile organic compounds in breath of patients with schizophrenia. *J Clin Pathol* 1995; **48**: 466–469.
115. Julak J, Stranska E, Rosova U, Geppert H, Spanel P, Smith D. Bronchoalveolar lavage examined by solid phase microextraction, gas chromatography-mass spectrometry and selected ion flow tube mass spectrometry. *J Microbiol Methods* 2006; **65**: 76–86.
116. Chapman E A, Thomas P S, Yates D H. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. *J Breath Res* 2010; **4**: 034001.
117. Ligor T, Szeliga J, Jackowski M, Buszewski B. Preliminary study of volatile organic compounds from breath and stomach tissue by means of solid phase microextraction and gas chromatography-mass spectrometry. *J Breath Res* 2007; **1**: 016001.
118. Phillips M, Cataneo R N, Greenberg J, Grodman R, Salazar M. Breath markers of oxidative stress in patients with instable angina. *Heath Dis* 2003; **5**: 85–99.
119. Moretti M, Phillips M, Abouzeid A, Cataneo R N, Greenberg J. Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. *Am J Obstet Gynecol* 2004; **190**: 1184–1190.
120. Maruniak J A, Silver W L, Moulton D G. Olfactory receptors respond to blood-borne odorants. *Brain Res* 1983; **265**: 312–316.
121. Stein D J, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome an obsessive-compulsive spectrum disorder?: two cases and a discussion. *J Neuropsychiatry Clin Neurosci* 1998; **10**: 96–99.
122. Phillips K A, Menard W. Olfactory reference syndrome: demographic and clinical features of imagined body odour. *Gen Hosp Psychiatry* 2011; **33**: 398–406.
123. Cruzado L, Cáceres-Taco E, Calizaya J R. Apropos of an olfactory reference syndrome case. *Actas Esp Psiquiatr* 2012; **40**: 234–238.
124. Wise P M, Eades J, Tjoa S, Fennessey P V, Preti G. Individuals reporting idiopathic malodour production: demographics and incidence of trimethylaminuria. *Am J Med* 2011; **124**: 1058–1063.
125. Bromley S M. Smell and taste disorders: a primary

- care approach. *Am Fam Physician* 2000; **61**: 427–436, 438.
126. Pacheco-Galván A, Hart S P, Morice A H. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. *Arch Bronconeumol* 2011; **47**: 195–203.
  127. Cailleux A, Allain P. Isoprene and sleep. *Life Sci* 1989; **44**: 1877–1880.
  128. Nachnani S. The effects of oral rinse on halitosis. *J Calif Dent Assoc* 1997; **25**: 145–150.
  129. Schwarz K, Pizzini A, Arendacká B *et al*. Breath acetone—aspects of normal physiology related to age and gender as determined in a PTR-MS study. *J Breath Res* 2009; **3**: 027003.
  130. Tangerman A. Measurement and biological significance of the volatile sulphur compounds hydrogen sulphide, methanethiol and dimethyl sulphide in various biological matrices. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; **877**: 3366–3377.
  131. Calil C M, Klein F. Influence of anxiety on the production of oral volatile sulphur compounds. *Life Sci* 2006; **79**: 660–664.
  132. Oral malodor. ADA council on scientific affairs. *J Am Dent Assoc* 2003; **134**: 209–214
  133. Aydin M. *Gas measurement protocols in halitosis patients*. (Unpublished data)
  134. Rosenberg M, Kozlovsky A, Gelernter I *et al*. Self-estimation of oral malodour. *J Dent Res* 1995; **74**: 1577–1582.
  135. Pham T A, Ueno M, Shinada K, Kawaguchi Y. Comparison between self-perceived and clinical oral malodour. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012; **113**: 70–80.
  136. Pham T A. Comparison between self-estimated and clinical oral malodour. *Acta Odontol Scand* 2013; **71**: 263–270.
  137. Fernández J R, Pereiro R, Medel A S. Optical fibre sensor for hydrogen sulphide monitoring in mouth air. *Analytica Chimica Acta* 2002; **471**: 13–23.
  138. Wallace K J, Cordero S R, Tan C P, Lynch V M, Anslyn E V. A colorimetric response to hydrogen sulphide. *Sens Actuat B Chem* 2007; **120**: 362–367.
  139. Mitsubayashia K, Minamide T, Otsuka K, Kudo H, Saito A. Optical bio-sniffer for methyl mercaptan in halitosis. *Analytica Chimica Acta* 2006; **573–574**, 575–580.
  140. Halimeter® Interscan Corporation. *Measure bad breath scientifically*. Chatsworth, CA, USA: Halimeter®. Online information available at <http://www.halimeter.com/the-halimeter-measure-bad-breath-scientifically/> (accessed March 2014).
  141. New Cosmos Electric Co., Ltd. *Breathtron®*. Osaka, Japan: New Cosmos Electric Co., Ltd. Online information available at <http://www.new-cosmos.co.jp/en/profile.html> (accessed March 2014).
  142. Tanda N, Washio J, Ikawa K, Suzuki K, Koseki T, Iwakura M. A new portable sulphide monitor with a zinc-oxide semiconductor sensor for daily use and field study. *J Dent* 2007; **35**: 552–557.
  143. Abimedical Corporation. *OralChroma™*. Osaka, Japan: Abimedical Corporation. Online information available at [http://www.abimedical.com/en/medical/product\\_01.html](http://www.abimedical.com/en/medical/product_01.html) (accessed March 2014).
  144. Yaegaki K, Brunette DM, Tangerman A, Choe YS, Winkel EG, Ito S, Kitano T, Ii H, Calenic B, Ishkitiev N, Ima T. Standardization of clinical protocols in oral malodor research. *J Breath Res* 2012; **6**: 017101.
  145. Diamond General Development Corp. *Diamond Probe/Perio 2000*. Online information available at <http://www.e-dental.com/doc/periodontal-probe-0001> (accessed March 2014).
  146. Intopsys. *Cyranose® 320. Cyranose Electronic Nose*. Online information available at <http://www.sensigent.com/products/cyranose.html> (accessed March 2014).
  147. Tamaki N, Kasuyama K, Esaki M, Toshikawa T, Honda SI, Ekuni D, Tomofuji T, Morita M. A new portable monitor for measuring odorous compounds in oral, exhaled and nasal air. *BMC Oral Health* 2011; **11**: 15.
  148. Cheng Z J, Warwick G, Yates D H, Thomas P S. An electronic nose in the discrimination of breath from smokers and non-smokers: a model for toxin exposure. *J Breath Res* 2009; **3**: 036003.
  149. Tamaki N, Kasuyama K, Esaki M *et al*. A new portable monitor for measuring odorous compounds in oral, exhaled and nasal air. *BMC Oral Health* 2011; **11**: 15.
  150. Pratten J, Pasu M, Jackson G, Flanagan A, Wilson M. Modelling oral malodour in a longitudinal study. *Arch Oral Biol*. 2003; **48**: 737–743.
  151. Yaegaki K, Brunette D M, Tangerman A *et al*. Standardization of clinical protocols in oral malodour research. *J Breath Res* 2012; **6**: 017101.
  152. Furne J, Majerus G, Lenton P, Springfield J, Levitt D G, Levitt M D. Comparison of volatile sulphur compound concentrations measured with a sulphide detector vs. gas chromatography. *J Dent Res* 2002; **81**: 140–143.
  153. Aydin M. Treatment of halitosis. presented at: 6th international congress of the Istanbul University Dentistry Faculty 2013 Nov 21–23, Istanbul, Türkiye
  154. Costello B P, Ewen R J, Ratcliffe N M. A sensor system for monitoring the simple gases hydrogen, carbon monoxide, hydrogen sulphide, ammonia and ethanol in exhaled breath. *J Breath Res* 2008; **2**: 037011.
  155. QuinTron. *BreathTracker: breath hydrogen and methane analysis with sample correction feature*. USA: QuinTron. Online information available at [http://www.quintron-eu.com/catalog/11\\_QT02444\\_Catalog.pdf](http://www.quintron-eu.com/catalog/11_QT02444_Catalog.pdf) (accessed March 2014).
  156. Rösing C K, Loesche W. Halitosis: an overview of epidemiology, aetiology and clinical management. *Braz Oral Res* 2011; **25**: 466–471.
  157. Lin M I, Flaitz C M, Moretti A J, Seybold S V, Chen J W. Evaluation of halitosis in children and mothers. *Paediatr Dent* 2003; **25**: 553–558.
  158. Suzuki N, Yoneda M, Naito T, Iwamoto T, Hirofujii T. Relationship between halitosis and psychological status. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; **106**: 542–547.
  159. Halimeter. *Halimeter® simplified operating instructions*. Online manual available at <http://www.halimeter.com/operating-instructions/> (accessed March 2014).
  160. Suzuki N, Yoneda M, Naito T *et al*. Association between oral malodour and psychological characteristics in subjects with neurotic tendencies complaining of halitosis. *Int Dent J* 2011; **61**: 57–62.
  161. Tanaka M, Anguri H, Nishida N, Ojima M, Nagata H, Shizukuishi S. Reliability of clinical parameters for predicting the outcome of oral malodour treatment. *J Dent Res* 2003; **82**: 518–522.
  162. Nachnani S. *Efficacy of zinc chloride based mouth rinse (BreathRx™) compared to chlorine dioxide based mouth rinse (Oxyfresh™)*. UCLA School of Dentistry, 2000. Online article available at [http://www.halitosis-research.com/Zinc\\_Chloride\\_Compared\\_to\\_Chlorine\\_Dioxide\\_Mouthrinse.html](http://www.halitosis-research.com/Zinc_Chloride_Compared_to_Chlorine_Dioxide_Mouthrinse.html) (accessed March 2014).
  163. Vandekerckhove B, Van den Velde S, De Smit M *et al*. Clinical reliability of non-organoleptic oral malodour measurements. *J Clin Periodontol* 2009; **36**: 964–969.
  164. Kleinberg I, Codipilly D M. Cystein challenge testing: a powerful tool for examining oral malodour processes and treatments *in vivo*. *Int Dent J* 2002; **52**: 221–228.